Recombinant CD4 (Clenoliximab Biosimilar) antibody

Catalog No. ABIN5668247

This Human Monoclonal antibody specifically detects in BR, ELISA, FACS, IHC and SPR. It exhibits reactivity toward Human and Chimpanzee.

Quick Overview for Recombinant CD4 (Clenoliximab Biosimilar) antibody (ABIN5668247)

Target: CD4 (Clenoliximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human, Chimpanzee

Host: Human

Clonality: Monoclonal

Conjugate: Un-conjugated

Application: Blocking Reagent (BR), ELISA, Flow Cytometry (FACS), Immunohistochemistry (IHC), Surface Plasmon Resonance (SPR)

Clone: CE9-1

Product Details

Purpose: Anti-CD4 [CE9.1 (Clenoliximab)], Human IgG4, lambda

Specificity: The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 μg/mL.

Cross-Reactivity: Chimpanzee

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG4 (primatized)

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Domain 1 of human CD4.

Isotype: IgG4 lambda

Application Details

Application Notes: The antibody binds specifically to CD4, a molecule which is part of the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 Molecule acts as a co-receptor in the activation of T cells, aiding the interaction between the TCR and MHC II of the antigen-presenting cell. The antibody is classified as "primatized", as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and γ4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody Keliximab by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec.

Comment:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details

Target: CD4 (Clenoliximab Biosimilar)

Target Type: Biosimilar

Background: P55, T cell surface antign T4/Leu-3.

UniProt: P01730